- |||||||||| Xolair (omalizumab) / Roche, Novartis
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis (clinicaltrials.gov) - Apr 4, 2018 P2/3, N=11, Completed, N=300 --> 650 | Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2018 --> May 2019 Recruiting --> Completed | N=24 --> 11 | Trial completion date: Mar 2019 --> Sep 2017 | Trial primary completion date: Dec 2018 --> Sep 2017
- |||||||||| Biomarker, Trial completion, Enrollment change, Trial primary completion date, Metastases: Simple Intensive Care Studies I (SICS-I) (clinicaltrials.gov) - Jan 23, 2018
P=N/A, N=1090, Completed, N=18 --> 0 | Recruiting --> Withdrawn | Trial completion date: Mar 2020 --> Feb 2018 | Trial primary completion date: Mar 2018 --> Feb 2018 Recruiting --> Completed | N=1500 --> 1090 | Trial primary completion date: Dec 2017 --> Jul 2017
- |||||||||| trimethoprim/sulfamethoxazole / Generic mfg.
Trial completion: A Non-Interventional Safety Study of Balsamic Bactrim (clinicaltrials.gov) - Nov 7, 2017 P=N/A, N=52, Completed, Recruiting --> Completed | N=1500 --> 1090 | Trial primary completion date: Dec 2017 --> Jul 2017 Recruiting --> Completed
- |||||||||| trimethoprim/sulfamethoxazole / Generic mfg.
Enrollment open, Trial primary completion date: A Non-Interventional Safety Study of Balsamic Bactrim (clinicaltrials.gov) - Feb 9, 2017 P=N/A, N=50, Recruiting, Trial primary completion date: Jun 2017 --> Aug 2018 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2016 --> Jun 2017
- |||||||||| Trial completion, Enrollment change, HEOR, Patient reported outcomes: EQUAL: Exercise and Quality of Life in Leukemia Patients (clinicaltrials.gov) - Nov 23, 2016
P=N/A, N=18, Completed, Recruiting --> Completed | N=10 --> 13 | Trial primary completion date: Dec 2016 --> Sep 2016 Recruiting --> Completed | N=30 --> 18
|